By Fineline Cube 
British pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) and Syndivia announced on October 27, 2025, that they have entered into an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical Antibody-Drug Conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).
Innovative ADC Technology
The ADC leverages Syndivia’s next-generation GeminiMab conjugation technology, demonstrating enhanced anti-tumor activity and a promising safety profile. Preclinical studies indicate the ADC can shrink tumors effectively without a proportional increase in significant side effects, even at higher doses, highlighting its potential as a best-in-class therapy.
Collaboration Terms
Under the agreement, Syndivia will receive an upfront payment, development and commercial milestone payments totaling up to £268 million, and tiered royalties on future product sales. GSK will take full responsibility for the ADC program’s development, manufacturing, and global commercialization.-Fineline Info & Tech